A Retrospective, Observational Study on the Effectiveness of Daclatasvir-Containing Regimens in Patients in KSA, UAE and Qatar

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Hepatitis C

Treatments: Other: Non-Interventional

Study type: Observational

Funder types: Industry

Identifiers

NCT03205618

AI444-382

Details and patient eligibility

About

The study will provide safety and efficacy information among patients receiving daclatasvir. It will describe daclatasvir prescribing patterns and provide a clinical profile of patients receiving the treatment in KSA, UAE, and Qatar.

Enrollment: 182 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients greater than or equal to 18 years of age
• Diagnosed with chronic hepatitis C
• Ended treatment with daclatasvir-containing regimen no later than 01-Oct-2015

Exclusion criteria

• Use of a daclatasvir-containing regimen in a clinical trial setting

Other protocol defined inclusion/exclusion criteria could apply

Trial design

182 participants in 1 patient group

daclatasvir patients in KSA, UAE, and Qatar

Description:

patients treated with daclatasvir-containing regimens in KSA, UAE, and Qatar

Treatment:

Other: Non-Interventional